Explore our materials

European Meeting on HIV & Hepatitis 2018

Management of hepatitis C therapy failures - virological perspective | Francesca Ceccherini– Silberstein, PhD

European Meeting on HIV & Hepatitis 2018

Novel simplified bioinformatics for NGS data analysis | Marc Noguera-Julian, PhD

European Meeting on HIV & Hepatitis 2018

New technologies reaching the clinic | Martin Däumer, MSc

Jonathan Schapiro

European Meeting on HIV & Hepatitis 2018

Implications for clinical practice | Jonathan Schapiro, MD

European Meeting on HIV & Hepatitis 2018

Clinical trial data 3 vs 2 drug regimens | Andrea De Luca, MD

European Meeting on HIV & Hepatitis 2018

Influence of resistance in the future | Richard Harrigan, MD

Pep Coll

MD, MS

European Meeting on HIV & Hepatitis 2018

The current status of PrEP in Europe | Pep Coll, MD

European Meeting on HIV & Hepatitis 2018

A new wild-type HIV in the era of transmitted drug resistance | Kristof Theys, PhD

Pep Coll

MD, MS

European Meeting on HIV & Hepatitis 2018

Long acting HIV drugs for prevention: what are the data? | Pep Coll, MD

Anton Pozniak

MD, FRCP

European Meeting on HIV & Hepatitis 2018

Long acting HIV drugs for treatment: what are the data? | Anton Pozniak, MD, FRCP

Saye Khoo

MD, PhD

European Meeting on HIV & Hepatitis 2018

Improving drug delivery: what are the new technologies? | Saye Khoo, MD, PhD